Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

Health authorities in Kerala have reported a positive case of Nipah virus infection in a man from Kozhikode, triggering precautionary measures across the district.

The patient tested positive in a preliminary test conducted in Kozhikode and is currently undergoing treatment at Kozhikode Medical College Hospital, officials said.

With the fresh scare, health authorities have initiated extensive contact tracing and surveillance measures to prevent any potential spread of the infection.

According to officials, the patient arrived at the hospital through the outpatient department and is believed to have interacted with several people before being identified as a suspected Nipah case.

While the initial test indicated the presence of the virus, confirmation from a specialized virology laboratory is still awaited. Despite the pending confirmatory result, the state government has activated containment protocols as a precaution. Close contacts of the patient are being identified, monitored, and assessed as part of the standard public health response.

Kerala Health Minister Says No Need for Panic

Also read: Bangladesh Battles Growing Measles Outbreak As Confirmed Cases Approach 10,000

Kerala Health Minister K. Muralidharan said the patient had extensive contacts but stressed that there was no reason for panic at this stage. The minister noted that the patient had visited multiple departments of the private hospital where he first sought treatment, raising concerns about possible exposure to others.

As a precautionary measure, hospital staff who may have come into contact with the patient have been asked to undergo quarantine and monitoring.

What Is Nipah Virus?

Read More: US Pushes Europe for Ebola Travel Curbs Ahead of FIFA World Cup: Which Countries Have Bans And Do They Work?

According to the World Health Organization, Nipah virus is a zoonotic disease, meaning it can spread from animals to humans. It can also be transmitted through contaminated food and, in some cases, directly from person to person.

In humans, Nipah infection can range from asymptomatic illness to severe respiratory disease and fatal encephalitis (brain inflammation). The virus can also infect animals such as pigs, causing significant economic losses for farmers.

Although only a limited number of outbreaks have been reported in Asia, the virus is known for its high fatality rate and potential to cause severe disease.

How Does Nipah Spread?

• Animal-to-Human Transmission: During the first recognized outbreak in Malaysia, which also affected Singapore, most human infections were linked to direct contact with infected pigs or their contaminated tissues. Transmission was believed to occur through exposure to respiratory secretions or bodily fluids of infected animals.

• Bat-Contaminated Food: In later outbreaks in Bangladesh and India, the most likely source of infection was the consumption of fruits or fruit products—particularly raw date palm sap—contaminated by saliva or urine from infected fruit bats.

• Human-to-Human Transmission: Human-to-human transmission has also been documented, particularly among family members and healthcare workers caring for infected patients.

Nipah Virus: Symptoms

Symptoms of Nipah virus infection may include:

• Fever
• Headache
• Breathing difficulties
• Cough and sore throat
• Diarrhea
• Vomiting
• Muscle pain
• Severe weakness
• Dizziness
• Altered consciousness in severe cases
• Encephalitis (brain inflammation)

Why Is Nipah A Concern?

Nipah virus is considered a major public health threat because of its high mortality rate, ability to spread through close contact, and the absence of a specific antiviral treatment or approved vaccine for widespread use.

Early detection, isolation of suspected cases, contact tracing, and strict infection-control measures remain the most effective tools for preventing outbreaks.

A federally commissioned study that concluded even low levels of alcohol consumption may increase the risk of disease and premature death has now been published in a scientific journal after its findings were set aside by the Trump administration.

The study, known as the Alcohol Intake and Health Study, was commissioned as part of an effort to update the United States Dietary Guidelines. Researchers concluded that consuming as little as one alcoholic drink per day could raise the risk of serious illness and mortality.

However, the report was never officially released by the administration and later became the subject of political and industry scrutiny.

Why Was the Study Not Released?

Launched in 2023, the Alcohol Intake and Health Study was overseen by the Substance Abuse and Mental Health Services Administration (SAMHSA).

The review aimed to inform recommendations on alcohol consumption in the next edition of the federal dietary guidelines. But soon the study garnered controversy with some members of Congress and alcohol lobby groups arguing that scientists involved in the review held anti-alcohol views, according to Stat News.

As per a House Oversight Committee report, released in January, the study was "irretrievably flawed". It recommended that federal officials disregard its findings when drafting dietary guidance.

However, researchers involved in the project argued that the findings were sidelined because they conflicted with the interests of the alcohol industry.

What Did The Study Find?

Also read: Is There A Safe Limit For Alcohol Consumption? Major Review Challenges Long-Held Beliefs

After the federal review was shelved, researchers submitted their work independently to the Journal of Studies on Alcohol and Drugs, where it was published following peer review.

The published analysis concluded that even modest alcohol consumption — roughly one drink per day — is associated with increased risks of disease and death.

“These findings are not radical. They are rigorous — and commercially threatening,” wrote Robert Vincent, a former SAMHSA associate administrator for alcohol prevention and treatment policy, in an accompanying editorial.

Vincent, who helped oversee the project, lost his position during broader cuts across federal health agencies last year, the report said.

Notable, the US Department of Health and Human Services (HHS) has stated that the now published article was not the same report reviewed by the government and emphasized that it was not commissioned, approved, or cleared by SAMHSA.

Alcohol Guidance Changed

Read More: X-Men Star Tyler Mane Reveals ‘Super-Rare’ Male Breast Cancer Diagnosis

Federal officials said they reviewed a broad range of scientific evidence when updating the nation's dietary recommendations.

New dietary guidelines released in January marked a significant shift in alcohol messaging. Rather than recommending specific daily limits, the guidance now advises Americans to “consume less alcohol for better overall health.”

According to HHS, the recommendation was based on a separate scientific review rather than the SAMHSA-led report.

For the first time in 20 years, the US Food and Drug Administration (FDA) has added bemotrizinol to the list of permitted sunscreen active ingredients.

Bemotrizinol is the first new active ingredient added to the over-the-counter (OTC) sunscreen monograph since the late 1990s and has been used for years in Europe and Asia.

“As promised in the Trump Administration’s MAHA Strategy Report, HHS is advancing innovation by bringing a new sunscreen ingredient to the US market for the first time in 20 years,” said HHS Secretary Robert F. Kennedy Jr.

“Bemotrizinol has been used safely in Europe for decades, and FDA’s action will increase competition and consumer confidence in sunscreen products.”

On December 11, 2025, the FDA proposed allowing the use of bemotrizinol in sunscreens. The agency finalized the action within seven months of issuing the proposed order.

Bemotrizinol is known to provide stable, long-lasting protection against both types of ultraviolet (UV) rays that can damage the skin. According to the FDA, it is also gentle enough to be used safely by young children.

What Is Bemotrizinol?

Also read: X-Men Star Tyler Mane Reveals ‘Super-Rare’ Male Breast Cancer Diagnosis

Bemotrizinol, also known as BEMT, is a chemical sunscreen filter that absorbs both UVB and UVA rays. The sun emits ultraviolet radiation, which sunscreen products are designed to block.

UVA and UVB rays affect the skin differently. UVA rays are primarily associated with tanning and skin ageing, while UVB rays are more closely linked to sunburn. UVB rays can also be partially blocked by barriers such as windows and clouds.

According to the University of Texas MD Anderson Cancer Center, about 95 per cent of the UV radiation reaching the Earth's surface is UVA, while UVB accounts for the remaining 5 per cent.

Sunscreens protect the skin either by creating a physical barrier using mineral ingredients or by using chemical filters that absorb UV radiation before it reaches the skin. Bemotrizinol belongs to the latter category.

The addition of BEMT is being welcomed by many experts because options that are both highly effective and considered safe remain limited in the US sunscreen market, according to an annual report by the Environmental Working Group (EWG), a nonprofit health and environmental advocacy organization.

Why Is Bemotrizinol Considered Beneficial?

Read More: Confused By Your Cholesterol Report? Here's What LDL And ApoB Really Mean

Bemotrizinol offers several characteristics that make it an effective sunscreen ingredient. It provides broad-spectrum protection against both UVA and UVB radiation and can achieve higher SPF protection at lower concentrations than some other commonly used sunscreen chemicals, according to Certified Laboratories and the FDA.

The ingredient is also photostable, meaning it breaks down more slowly when exposed to sunlight, helping maintain protection for longer periods. Because it is oil-soluble, it can be easily incorporated into creams and lotions.

In addition, bemotrizinol is minimally absorbed through the skin and rarely causes irritation, which is one reason the FDA considers it safe for use in children as young as six months old.

Bemotrizinol Added to OTC

Meanwhile, DSM Nutritional Products, a manufacturer submitted an OTC monograph order request seeking to add bemotrizinol, marketed as Parsol Shield, at concentrations of up to 6 per cent as a new active ingredient in the OTC sunscreen monograph.

“The FDA reviewed the request and proposed to amend the OTC monograph to add bemotrizinol as a sunscreen active ingredient,” the agency said in its announcement.

In December 2025, DSM had announced that, once approved, Parsol Shield would be available for use in sunscreen products in accordance with the monograph requirements.

According to the FDA, OTC monograph drugs such as sunscreens can enter the market without an approved drug application if they meet specific requirements, including permitted active ingredients, uses and dosage limits established under the monograph.

The FDA can modify an OTC monograph through an administrative order, and manufacturers can initiate the process by submitting an OTC monograph order request.